Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma

Primary liver cancer has become the second most fatal cancer in the world, and its five-year survival rate is only 10%. Most patients are in the middle and advanced stages at the time of diagnosis, losing the opportunity for radical treatment. Liver cancer is not sensitive to chemotherapy or radioth...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Mengjiao, Yang, Liu, Lin, Yanjie, Lu, Yao, Bi, Xiaoyue, Jiang, Tingting, Deng, Wen, Zhang, Lu, Yi, Wei, Xie, Yao, Li, Minghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524074/
https://www.ncbi.nlm.nih.gov/pubmed/36175957
http://dx.doi.org/10.1186/s12951-022-01615-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524074/
https://www.ncbi.nlm.nih.gov/pubmed/36175957
http://dx.doi.org/10.1186/s12951-022-01615-2

Ejemplares similares